[Therapeutic efficacy of 4-(adamantyl-1)-1-(1-aminobutyl) benzene in experimental fungal pathology].
Antifungal activity of an adamantane derivative, i. e. 4-(adamantyl-1)-1-(1-aminobutyl) benzol was studied in experiments in vivo in a model of generalized infection and local skin injury. In doses of 0.1 LD50, 0.001 LD50, 0.001 LD50 (intraperitoneal administration) it had a therapeutic effect on generalized candidiasis and promoted 60-80-percent survival of the laboratory animals. Its application as 1-percent ointment to Candida albicans infected skin prevented the wound formation in rabbits and showed therapeutic efficacy in the treatment of infected wounds in albino rats.
Vrynchanu
N A
NA
D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D051379:Mice
C526861:4-(adamantyl-1)-1-(1-aminobutyl)benzol; D000935:Antifungal Agents; D000218:Adamantane